Navigation Links
InfraReDx Announces Publication of a Case Report in Circulation Highlighting Novel Clinical Finding with LipiScan™ Coronary Imaging System
Date:12/7/2010

BURLINGTON, Mass., Dec. 7, 2010 /PRNewswire/ -- InfraReDx, Inc., a medical device company developing intelligent cardiovascular diagnostic imaging technologies, today announced the publication of a case report in Circulation describing the association of stent thrombosis with lipid core plaque as detected by its LipiScan™ Coronary Imaging System. The LipiScan is the first and only FDA-approved system to provide a Chemogram™ (map of lipid core plaque) within the imaged vessel via near-infrared (NIR) spectroscopy. The authors note that the case represents the first demonstration of acute stent thrombosis associated with disrupted lipid core plaque (LCP) as detected by NIR imaging with the LipiScan system.

The paper titled "Residual Thrombogenic Substrate After Rupture of a Lipid Rich Plaque – Possible Mechanism of Acute Stent Thrombosis? A Near-Infrared Spectroscopy Study" was published in Circulation (2010;122:2349-2350) under authors Sakhuja R., Suh W., Jaffer F. and Jang I.

"While stenting is an excellent means to treat flow restrictions caused by coronary plaques, it is in some cases complicated by thrombosis which may cause serious consequences," said James E. Muller, M.D., founder and chief executive officer of InfraReDx. "This report by Sakhuja et al. describes the occurrence of thrombosis in a stent that ends in a lipid core plaque, a structure that contains substances known to be thrombogenic. This adds to the accumulating evidence that many complications of stenting – peri-stenting infarction, stent thrombosis and restenosis – are due not to features of the stent or stenting technique, but to the presence of a lipid core plaque at the stented site. We are pleased to make available the LipiScan IVUS Coronary Imaging System, which provides an easy and accurate method to detect lipid core plaque and thereby adds important information to the decision-making process."

Since this LipiScan examination was performed, InfraReDx has received FDA clearance (see September 1, 2010 news release) for its next-generation LipiScan IVUS Coronary Imaging System, which now combines both NIR (LipiScan) and intravascular ultrasound (IVUS) technologies. The IVUS feature provides an image of the plaque and coronary artery lumen, while the NIR feature provides rapid and accurate assessment of LCPs. Upon completion of a single catheter pullback, the LipiScan IVUS system is able to immediately generate and display a grayscale IVUS image of the coronary artery, along with a complete and co-registered Chemogram within the imaged vessel.

About InfraReDx, Inc.InfraReDx, Inc. is a privately funded medical device company improving patient care through the development and commercialization of intelligent imaging technologies to improve the diagnosis and treatment of coronary artery disease. InfraReDx's LipiScan™ IVUS Coronary Imaging System is the first and only available catheter to combine both near-infrared spectroscopy (NIR) and intravascular ultrasound (IVUS) technologies to both visualize and characterize the intracoronary lipid core plaques (LCP) suspected of causing the majority of heart attacks. Founded in 1998, InfraReDx is headquartered in Burlington, Massachusetts. For more information, visit www.infraredx.com.  Contacts:Susan Heins (media)Pure Communications, Inc.864-286-9597sjheins@purecommunicationsinc.com Grant FrazierVice President of MarketingInfraReDx, Inc.781-345-9632gfrazier@infraredx.com
'/>"/>

SOURCE InfraReDx, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. FDA Grants Market Clearance for the LipiScan(TM) Coronary Imaging System Developed by InfraReDx, Inc. - A Novel Spectroscopy System for the Identification of Lipid Core Containing Plaques of Interest in the Coronary Arteries
2. First Use in a Patient of The InfraReDx LipiScan(TM) Coronary Imaging System
3. InfraReDx to Showcase the LipiScan(TM) Coronary Imaging System at the Cardiovascular Research Foundations (CRF) Annual Transcatheter Cardiovascular Therapeutics (TCT) Scientific Meeting
4. InfraReDxs LipiScan(TM) Coronary Imaging System for Identification of Lipid Core Plaque to be Highlighted at 59th Annual Scientific Session of the American College of Cardiology
5. InfraReDxs New LipiScan™ IVUS Coronary Imaging System to be Highlighted at TCT 2010
6. InfraReDx Completes $21 Million Equity Financing
7. InfraReDx Announces Presentation of LipiScan™ Research at American Heart Association Scientific Sessions 2010
8. InfraReDx to Present at Canaccord Genuity 5th Annual Cardiovascular, Diabetes & Obesity Conference
9. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
10. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
11. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/11/2017)... 11, 2017  Thornhill Research Inc. ( ... an $8,049,024 USD five-year, firm-fixed-priced, indefinite-quantity/indefinite-delivery contract by ... Commercial Corporation (CCC) ( Ottawa, Ontario, Canada ... administer general anesthesia to patients requiring emergency medical ... US Marine Corps have been a longtime partner ...
(Date:5/10/2017)... , May 10, 2017 Radiology has become ... its costs have also spiraled to the number one ... to radiology than ever before as the most complete ... a patient with lower back pain an MRI may ... reason for pain, resulting in entirely different treatment protocols.  ...
(Date:5/9/2017)... , May 9, 2017  Oramed Pharmaceuticals Inc. ... a clinical-stage pharmaceutical company focused on the development ... the Canadian Intellectual Property Office has granted Oramed ... Administration of Exenatide". The patent covers Oramed,s invention ... GLP-1 is an incretin hormone that stimulates ...
Breaking Medicine Technology:
(Date:5/26/2017)... Santa Clara, Calif. (PRWEB) , ... May 26, ... ... technology, announces the integration of the CareFusion NOX-T3 portable sleep monitor with its ... that provides a consistent, browser-based interface for diagnostic device operations. With this platform, ...
(Date:5/26/2017)... , ... May 26, 2017 , ... After raising nearly ... Top gadget will continue to be available at a discounted crowdfunding price on ... stress wherever they are, I also wanted to bring a fidget toy to the ...
(Date:5/26/2017)... ... May 26, 2017 , ... “When the Stars Lead ... is the creation of published author Laura Weigel Douglas, an avid reader who lives ... a house that sometimes feels like Green Hills Adventure Camp. She couldn’t be more ...
(Date:5/26/2017)... ... May 26, 2017 , ... Water damage to the flooring of ... District had left education officials with a number of critical issues to address before ... had to be accomplished with little or no disruption to class schedules. Second, the ...
(Date:5/24/2017)... San Diego, California (PRWEB) , ... May 24, ... ... patient care through innovative medical image management and interpretation, has received U.S. Food ... technology. , Nucleus.io is a web-based, scalable and secure cloud platform for ...
Breaking Medicine News(10 mins):